Found 98 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
DEVELOPING ORAL LT3 THERAPY FOR HEART FAILURE (DOT3HF)
Parallel, Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial The primary objective is to evaluate the safety of oral LT3 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) The secondary objective is to evaluate the feasibility and preliminary efficacy outcomes of oral LT3 therapy …
A Randomized Double-blind Multicenter Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants with Treatment-resistant Depression
this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from …
A multicenter double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)
The purpose of this study is to find out if the investigational drug, apraglutide and investigational drug , is able to reduce the volume per week of PS required in adults with short bowel syndrome and intestinal failure.
Prospective US Radiofrequency SUI Trial (PURSUIT)
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour …
A Randomized Double-blind Placebo-controlled Repeat-dose Multicenter Trial to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
Normal 0 false false false EN-US X-NONE X-NONE The main purpose of this study is to understand how patients with diffuse cutaneous systemic sclerosis (dcSSc) respond to an investigational drug called HZN-825. The study drug is being tested to determine if it will work and be safe for the treatment …
Artificial Intelligence (AI) Assisted Real-time Adenoma Detection During Colonoscopies (CAG-SIG-AI)
This is a pragmatic, double-blind, randomized, controlled trial, to evaluate the effect of implementing a Computer-assisted detection (CADe) system within the routine clinical practice of Canadian healthcare institutions. The main hypothesis of this study is that the ADR in the operating room equipped with the GI genius CADe system will …
The Randomized And Controlled Non-inferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-Coated Balloon
Prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects (at approximately 60 sites in the US and 18 sites outside the US) with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting eligibility criteria will be randomized 1:1 to treatment …
A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
Please choose between Voice or SMS based delivery of verification code
or